Search

Author/Creator Blagden, Sarah P

3. First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. Issue 10 (31st October 2022)

Authors:
Davis, Elizabeth J; Martin-Liberal, Juan; Kristeleit, Rebecca; Cho, Daniel C; Blagden, Sarah P; Berthold, Dominik; Cardin, Dana B; Vieito, Maria; Miller, Rowan E; Hari Dass, Prashanth; Orcurto, Angela; Spencer, Kristen; Janik, John E; Clark, Jason; Condamine, Thomas; Pulini, Jennifer; Chen, Xueju...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 10(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Issue 7 (July 2020)

Authors:
Blagden, Sarah P; Cook, Adrian D; Poole, Christopher; Howells, Lesley; McNeish, Ian A; Dean, Andrew; Kim, Jae-Weon; O'Donnell, Dearbhaile M; Hook, Jane; James, Elizabeth C; White, Ian R; Perren, Timothy; Lord, Rosemary; Dark, Graham; Earl, Helena M; Hall, Marcia; Kaplan, Richard; Ledermann, Jonat...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 7(2020)
Page Start:
969
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗